

IDEXX LABORATORIES INC /DE
 Form 4
 February 05, 2013

FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549

OMB APPROVAL
 OMB Number: 3235-0287
 Expires: January 31, 2005
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
 RAINES MERILEE

2. Issuer Name and Ticker or Trading Symbol
 IDEXX LABORATORIES INC /DE
 [IDXX]

5. Relationship of Reporting Person(s) to Issuer
 (Check all applicable)

(Last) (First) (Middle)
 ONE IDEXX DRIVE
 (Street)

3. Date of Earliest Transaction (Month/Day/Year)
 02/01/2013

____ Director _____ 10% Owner
 Officer (give title below) _____ Other (specify below)
 Executive VP & CFO

WESTBROOK, ME 04092

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
 Form filed by More than One Reporting Person

(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	02/01/2013		M	V Amount (A) or (D) Price	51,581	D	
Common Stock	02/01/2013		S	13,581 A \$ 34.37	38,000	D	
Common Stock	02/01/2013		S	31,900 D \$ 94.4108 (1)	6,100	D	
Common Stock	02/01/2013		S	6,100 D \$ 94.7466 (2)	0	D	
Common Stock	02/01/2013		S	29,052 D \$ 95.864 (3)	5,948	I	

Edgar Filing: IDEXX LABORATORIES INC /DE - Form 4

Common Stock					\$ 94.7439 (4)			by Charitable Remainder Trust
Common Stock	02/01/2013	S	5,948	D	\$ 95.8086 (5)	0	I	by Charitable Remainder Trust
Common Stock	02/04/2013	M	20,440	A	\$ 41.935	20,440	D	
Common Stock	02/04/2013	M	26,000	A	\$ 28.655	46,440	D	
Common Stock	02/04/2013	M	24,000	A	\$ 25.45	70,440	D	
Common Stock	02/04/2013	M	17,736	A	\$ 56.95	88,176	D	
Common Stock	02/04/2013	M	1	A	\$ 34.37	88,177	D	
Common Stock	02/04/2013	M	8,120	A	\$ 53.31	96,297	D	
Common Stock	02/04/2013	M	2,851	A	\$ 77.59	99,148	D	
Common Stock	02/04/2013	S	84,486	D	\$ 93.6295 (6)	14,662	D	
Common Stock	02/04/2013	S	4,862	D	\$ 94.3454 (7)	9,800	D	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Security (Instr. 3 and 4)
--	--	--------------------------------------	--	--------------------------------	---	--	---

Edgar Filing: IDEXX LABORATORIES INC /DE - Form 4

			Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Qualified Stock Option (right to buy)	\$ 34.37	02/01/2013	M			13,581	<u>(8)</u>	02/13/2016	Common Stock	13,581
Incentive Stock Option (right to buy)	\$ 41.935	02/04/2013	M			2,384	<u>(9)</u>	02/13/2014	Common Stock	2,384
Incentive Stock Option (right to buy)	\$ 28.655	02/04/2013	M			3,488	<u>(10)</u>	02/02/2015	Common Stock	3,488
Incentive Stock Option (right to buy)	\$ 25.45	02/04/2013	M			3,928	<u>(11)</u>	02/04/2014	Common Stock	3,928
Non-Qualified Stock Option (right to buy)	\$ 28.655	02/04/2013	M			22,512	<u>(12)</u>	02/02/2015	Common Stock	22,512
Non-Qualified Stock Option (right to buy)	\$ 41.935	02/04/2013	M			18,056	<u>(13)</u>	02/13/2014	Common Stock	18,056
Non-Qualified Stock Option (right to buy)	\$ 56.95	02/04/2013	M			17,736	<u>(14)</u>	02/13/2015	Common Stock	17,736
Incentive Stock Option (right to buy)	\$ 34.37	02/04/2013	M			1	<u>(15)</u>	02/13/2016	Common Stock	1
Non-Qualified Stock Option (right to buy)	\$ 53.31	02/04/2013	M			8,120	<u>(16)</u>	02/13/2017	Common Stock	8,120
Non-Qualified Stock Option (right to buy)	\$ 77.59	02/04/2013	M			2,851	<u>(17)</u>	02/13/2018	Common Stock	2,851
Non-Qualified Stock Option (right to buy)	\$ 25.45	02/04/2013	M			20,072	<u>(18)</u>	02/04/2014	Common Stock	20,072

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
RAINES MERILEE ONE IDEXX DRIVE			Executive VP & CFO	

WESTBROOK, ME 04092

Signatures

Conan R. Deady, Attorney-in-Fact for Merilee
Raines

02/05/2013

__Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
 - (1) The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from \$94.24 to \$94.64, inclusive. The reporting person hereby undertakes to provide upon request to SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 1, 2, 3, 4, 5, 6 and 7 to this Form 4.
 - (2) The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from \$94.22 to \$95.21, inclusive.
 - (3) The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from \$95.22 to \$96.18, inclusive.
 - (4) The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from \$94.24 to \$95.23, inclusive.
 - (5) The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from \$95.24 to \$96.19, inclusive.
 - (6) The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from \$93.26 to \$94.20, inclusive.
 - (7) The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from \$94.28 to \$94.46, inclusive.
 - (8) Grant of options to buy shares of common stock becomes exercisable as to 4,527 shares on 02/14/2010, 02/14/2011 and 02/14/2012, 4,526 shares on 02/14/2013, and the remaining 1,618 shares on 02/14/2014.
 - (9) Grant of options to buy shares of common stock that vest on the fifth anniversary date (02/14/2012) of the grant.
 - (10) Grant of options to buy shares of common stock that vest on the fifth anniversary date (02/03/2010) of the grant.
 - (11) Grant of options to buy shares of common stock that vest on the fifth anniversary date (02/05/2009) of the grant.
 - (12) Grant of options to buy shares of common stock becomes exercisable as to 5,200 shares on 02/03/2006, 02/03/2007, 02/03/2008, and 02/03/2009, and the remaining 1,712 shares on 02/03/2010.
 - (13) Grant of options to buy shares of common stock becomes exercisable as to 4,088 shares on 02/14/2008, 02/14/2009, 02/14/2010, and 02/14/2011, and the remaining 1,704 shares on 02/14/2012.
 - (14) Grant of options to buy shares of common stock becomes exercisable as to 4,434 shares on 02/14/2009, 02/14/2010, 02/14/2011, and 02/14/2012, and the remaining 2,678 shares on 02/14/2013.
 - (15) Grant of options to buy shares of common stock becomes exercisable as to 1 share on 02/14/2010 and 02/14/2013, and the remaining 2,909 shares on 02/14/2014.
 - (16) Grant of options to buy shares of common stock becomes exercisable as to 4,060 shares on 02/14/2011, 02/14/2012 and 02/14/2013, 4,059 shares on 02/14/2014, and the remaining 2,184 shares on 02/14/2015.
 - (17) Grant of options to buy shares of common stock becomes exercisable as to 2,851 shares on 02/14/2012, 02/14/2013, 02/14/2014 and 02/14/2015, and the remaining 1,563 shares on 02/14/2016.
 - (18) Grant of options to buy shares of common stock becomes exercisable as to 4,800 shares on 02/05/2005, 02/05/2006, 02/05/2007 and 02/05/2008, and the remaining 872 shares on 02/05/2009.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.